Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Innovation Council · Running

UniSens Universal GPCR Activity Sensor for Next Generation Drug Discovery

Coordinator
Isar Bioscience GmbH, Germany
Runs
1 November 2023 to 31 October 2027
Status
Running
EU funding
€3.0m
Total cost
€3.0m
Partners
8 organisations in 6 countries
Type
European Innovation Council
Grant agreement
101131014

What the project is doing

In the project's own words, from its summary on CORDIS.

This project by a consortium of academic labs and small biotech companies concerns a new key innovation for the development of drugs targeting G protein-coupled receptors (GPCRs). GPCRs are the most important class of therapeutic targets, both for current drugs and those under development, covering about a third of the €1.2 trillion pharmaceutical market. Recent research has revealed that GPCRs do not function as simple on/off switches but instead can adopt multiple conformations leading to complex textures of downstream effects.

Functionally selective drugs modulate the GPCR structure to stimulate certain downstream pathways over others. In the search for this next generation of better drugs, the pharmaceutical industry currently employs multiple (10+) distinct GPCR assays, performed in non-identical cellular contexts, and misleading readouts from this approach contribute significantly to costly drug failure. Here we propose a radically new single-assay technology platform that will enable detection and functional classification of drug candidates with superior confidence compared to today's approaches.

Its unique design supports streamlined drug discovery from the test tube to the native disease-relevant cell, as well as the capacity to efficiently harness artificial intelligence (AI) in the design of better drugs. The technology is based upon highly informative fluorescent sensor reagents that react to different receptor conformations with subtle, flexible changes in their structure. In this Pathfinder project, our main objective is to demonstrate that the conformational fingerprints generated by these sensors correlate to specific cellular signalling profiles, i.e.

GPCR activity states (proof of principle). We believe that the UniSens platform will become the standard tool for early drug development and could be a game-changer in the search for safer, more effective drugs.

Who is involved

OrganisationCityCountryRole
Isar Bioscience GmbHPlaneggGermanyCoordinator
Interax Biotech AGSchlierenSwitzerlandAssociatedpartner
Innovative Bioimaging SroPragueCzechiaParticipant
Univerzita KarlovaPraha 1CzechiaParticipant
Celtarys Research SLSantiago De CompostelaSpainParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceThird party
Stichting VuAmsterdamNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI